These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 3906168)
41. [Clinical evaluation of aspoxicillin in children]. Nakayama N; Yanagishima M; Tomimasu K; Tsuji Y Jpn J Antibiot; 1985 Jul; 38(7):1972-8. PubMed ID: 4068229 [TBL] [Abstract][Full Text] [Related]
42. Bactericidal activity of ertapenem against major intra-abdominal pathogens. Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463 [TBL] [Abstract][Full Text] [Related]
43. [The therapeutic effects of aspoxicillin on various infectious diseases in children]. Wakiguchi H; Maeda A; Ohara Y; Tone Y; Araki K; Shiraishi T; Ogura H; Kitamura I Jpn J Antibiot; 1985 Jul; 38(7):1925-30. PubMed ID: 4068226 [TBL] [Abstract][Full Text] [Related]
44. [Clinical experience with aspoxicillin in the pediatric field]. Kobashi H; Nishioka A; Miyamoto N; Oohara K; Okamoto T Jpn J Antibiot; 1985 Jul; 38(7):1911-7. PubMed ID: 3851863 [TBL] [Abstract][Full Text] [Related]
45. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643 [TBL] [Abstract][Full Text] [Related]
46. [Antimicrobial activities of aspoxicillin of fresh clinical isolates]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S Jpn J Antibiot; 1993 Apr; 46(4):295-309. PubMed ID: 8515561 [TBL] [Abstract][Full Text] [Related]
47. Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model. Bantar C; Fernandez Canigia L; Berger MA; Soutric JL; Arenoso HJ J Chemother; 2009 Jun; 21(3):296-301. PubMed ID: 19567350 [TBL] [Abstract][Full Text] [Related]
48. [Bacteriological and clinical evaluation of piperacillin in the field of obstetrics and gynecology]. Ninomiya K; Makino S; Hasegawa Y; Yoshimoto T; Masuda K; Hamaya K Jpn J Antibiot; 1982 Oct; 35(10):2323-9. PubMed ID: 6223149 [TBL] [Abstract][Full Text] [Related]
49. [Clinical studies of aspoxicillin in pediatrics]. Haruta T; Kuroki S; Okura K; Kobayashi Y Jpn J Antibiot; 1985 Jul; 38(7):1898-904. PubMed ID: 4068224 [TBL] [Abstract][Full Text] [Related]
50. Ciprofloxacin: a comparative evaluation of its bactericidal activity in human serum against four enterobacterial species. Weiss D; Trautmann M; Wagner J; Borner K; Hahn H Drugs Exp Clin Res; 1986; 12(11):889-94. PubMed ID: 3545730 [TBL] [Abstract][Full Text] [Related]
51. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics. Murakawa T; Sakamoto H; Hirose T; Nishida M Antimicrob Agents Chemother; 1980 Sep; 18(3):377-81. PubMed ID: 6999984 [TBL] [Abstract][Full Text] [Related]
52. [A clinical study on the penetration of aspoxicillin into tissue and wound exudates in breast cancer]. Tsuburaya H; Watanabe I; Takahashi M; Endo S Jpn J Antibiot; 1985 Jun; 38(6):1509-15. PubMed ID: 4046174 [TBL] [Abstract][Full Text] [Related]
53. [Bactericidal effects and combined action of micronomicin with beta-lactam antibiotics against Pseudomonas aeruginosa and Escherichia coli]. Yamashita K; Minagawa H; Sato K; Kitaura K; Okachi R Jpn J Antibiot; 1983 Jan; 36(1):189-93. PubMed ID: 6221129 [TBL] [Abstract][Full Text] [Related]
54. Effect of the hydroxyl group of the p-hydroxyphenyl moiety of aspoxicillin, a semisynthetic penicillin, on its pharmacokinetic property. Okuno S; Maezawa I; Sakuma Y; Matsushita T; Yamaguchi T J Antibiot (Tokyo); 1988 Feb; 41(2):239-46. PubMed ID: 3356612 [TBL] [Abstract][Full Text] [Related]
55. [In vitro study on efficacy of combination use of aspoxicillin and beta-lactam preparations (ceftazidime, cefmetazole and aztreonam) against bacteria isolated from abdominal infections]. Chimura T; Ise H; Misawa H Jpn J Antibiot; 1992 Jul; 45(7):763-73. PubMed ID: 1522668 [TBL] [Abstract][Full Text] [Related]
56. [Clinical evaluation of piperacillin in the urological field]. Hayashida S; Kitajima K; Joko K Hinyokika Kiyo; 1983 Apr; 29(4):465-76. PubMed ID: 6563846 [TBL] [Abstract][Full Text] [Related]
57. [Clinical laboratory approach in estimating effective administrative dose of piperacillin. Reevaluation of MIC break points in 3 and 4 category systems of disc susceptibility test]. Matsuo K; Uete T Jpn J Antibiot; 1990 Sep; 43(9):1559-71. PubMed ID: 2262963 [TBL] [Abstract][Full Text] [Related]
58. [Antibacterial activities of piperacillin in several fresh clinical isolates]. Matsuzaki K; Koyama H; Omika K; Hasegawa M; Sato Y; Kobayashi I; Kaku M Jpn J Antibiot; 2000 Aug; 53(8):573-81. PubMed ID: 11070819 [TBL] [Abstract][Full Text] [Related]
59. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. DeRyke CA; Banevicius MA; Fan HW; Nicolau DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197 [TBL] [Abstract][Full Text] [Related]
60. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli. Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]